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A B S T R A C T
Background
It has been reported that soluble HLA-G serum levels are increased in patients with pollen-induced allergic rhinitis
and decrease after immunotherapy. However, no functional study has been conducted so far. The aim of this study was to
evaluate the membrane expression and secretion of HLA-G molecules in peripheral blood mononuclear cells from aller-
gic rhinitis patients after in vitro incubation with the causal allergen.
Methods and results
Twenty-two allergic rhinitis patients and ten healthy subjects were enrolled. Membrane HLA-G expression was deter-
mined by flow cytometry and soluble HLA-G in culture supernatant was determined by immunoenzymatic assay. HLA-G
expression was detected in CD4+ (T-helper-2) cells and monocytes after in vitro stimulation with the causal allergen but
not with non specific stimuli and non causal allergens. Accordingly, the release of soluble HLA-G in culture supernatant
occurred only after the stimulation with the causal allergen. Collectively, these results were confirmed by Western blot
analysis.
Conclusions
The present study provides the first in vitro evidence that in allergic patients HLA-G expression and secretion is
specifically induced by the causal allergen. These data may add new insights into the pathogenetic mechanisms underly-
ing allergic inflammation and allergen specific immunotherapy.
© 2016 Published by Elsevier Ltd.
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1. Introduction
HLA-G is a human non-classical major histocompatibility com-
plex (MHC) molecule mainly expressed in membrane-bound form at
the fetal-maternal interface on the extravillous cytotrofoblast [1] and
in placental tissue [2] where it contributes to the development of ma-
ternal tolerance to the semi-allogeneic fetus [3]. It is also physiolog-
ically expressed in certain adult tissues such as thymus [4], cornea
[5], pancreas [6] and bronchial epithelial cells [7] as well as in differ-
ent cells types such as activated monocytes [8] and erythroid and en-
dothelial precursors [9]. The expression of HLA-G antigens has been
recently reported in some solid tumours, transplanted organs, cuta-
neous inflammatory diseases and on virally infected cells in several
pathological conditions [10,11]. HLA-G is also detectable as a solu-
ble form (sHLA-G) in several body fluids and derives from the shed-
ding of proteolytically cleaved surface isoforms (sHLA-G1) and/or the
secretion of soluble isoforms (HLA-G5, -G6 and -G7) [12–14]. Re
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cently it has been demonstrated that a significant proportion of
sHLA-G molecules is contained in microsomes or exosomes released
from cells [15–17]. Elevated levels of sHLA-G molecules have been
detected in plasma of patients affected by various pathological condi-
tions [18–23] and in cerebrospinal fluid of patients with multiple scle-
rosis [24].
Several immune regulatory functions have been attributed to both
membrane-bound and soluble HLA-G molecules [25,26]. Most of
them are immunosuppressive as they inhibit the cytolytic function of
NK cells and CD8+ T lymphocytes [27,28], the alloproliferative re-
sponse of CD4+ T cells [29], the maturation of dendritic cells [30]
and the activation of B cells [31]. In addition, HLA-G molecules
are able to trigger apoptosis in antigen-specific CD8+ T lymphocytes
[28,32,33]. HLA-G seems to be involved also in the tuning of im-
mune responses: in vitro studies indicate that incubation of peripheral
blood mononuclear cells (PBMC) with HLA-G expressing cells fa-
vors a shift towards a T helper (Th)-2 cytokine profile, while incuba-
tion with sHLA-G protein induces an anti-inflammatory environment
due to the release of inteleukin-10 [34,35] Finally, HLA-G-positive
CD4+ CD25− FoxP3+ regulatory T cells have been detected in periph-
eral blood and in inflamed tissues [36–39].
As far as allergic diseases are concerned, which are presently con-
sidered as disorders characterized by a dysfunction of immunoregu-
lation leading to an amplified Th-2 response [40,41], it has been re
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ported that elevated levels of sHLA-G molecules are detected in
plasma and bronchoalveolar lavage fluid of atopic asthmatics [42–45],
that the production of sHLA-G in unstimulated PBMC cultures is
significantly higher in subjects with occupational isocyanate-induced
asthma as compared with asymptomatic-exposed controls [46] and
that the amount of sHLA-G detected in the medium from PBMC stim-
ulated with allergen in vitro is reduced after specific immunotherapy
[47]. Moreover, previous studies in allergic rhinitis (AR) patients in-
dicated that sHLA-G serum levels were: i) significantly increased in
comparison with normal subjects; ii) elevated both outside and during
the pollen season in patients with seasonal allergy; and iii) correlated
with clinical severity, drug use, allergen-specific IgE levels, type of
allergy and response to immunotherapy [48–52]. However, to the best
of our present knowledge, no study has been performed to investigate
the effect of immune cell exposure to allergens in vitro on HLA-G
molecules in AR patients. Therefore, the aim of the present study was
to evaluate the membrane expression and secretion of HLA-G mole-
cules in immune cells from AR patients after in vitro incubation with
the causal allergen as well as with non-specific stimuli.
2. Materials and methods
2.1. Study population
Twenty-two allergic patients (11 males and 11 females, mean age
36.14 years) were enrolled in the study. Inclusion criteria were: pres-
ence of allergic rhinitis, documented by history of typical nasal symp-
toms, positive skin prick test for the specific allergen performed ac-
cording to validated criteria and demonstration of a cause/effect rela-
tionship between exposure to the sensitizing allergen and the occur-
rence of nasal symptoms (post hoc ergo propter hoc).
Patients with either acute upper respiratory infections, or under-
going specific immunotherapy, or using nasal or oral corticosteroids,
antileukotrienes and antihistamines within the previous 4 weeks were
excluded. Eighteen patients were mono-allergic to either Graminaceae
(n. 5), Parietaria (n. 7) or Dermatophagoides (n. 6), whereas 4 patients
were allergic to both Parietaria and Dermatophagoides. Patients were
evaluated during winter, such as outside the pollen season, but when
the exposure to mite was still present.
Ten healthy subjects (5 males and 5 females, mean age
38.26 years) were enrolled as controls. The study was conducted with
the approval of the local Ethics Committee and after obtaining the
written informed consent by all participants.
2.2. Cell cultures
Peripheral blood mononuclear cells (PBMC) were isolated from
heparinized venous blood samples (10 U/mL heparin) by Ficoll-Hy-
paque density gradient centrifugation (Lymphoflot, Biotest, Ger-
many). PBMC were then washed with phosphate-buffered saline
(PBS) and either utilized for membrane antigens assessment or cul-
tured up to 72 h in 96-well U-bottomed microplates (Becton Dickin-
son, CA, USA) with RPMI-1640 complete medium (Biochrom AG,
Germany) supplemented with 10% autologous plasma at 37 °C in a
5% CO2 atmosphere in humified air. PBMC were cultured in the ab-
sence (controls) or in the presence of the following stimuli or allergens
(kindly provided by Anallergo, Florence, Italy): phytohemoagglutinin
(PHA, 10 μg/ml, Sigma Aldrich, Italy), lipopolisaccaride (LPS, 20 μg/
ml, Sigma Aldrich, Italy), phorbol-myristate-acetate (PMA, 20 μg/
ml, Sigma Aldrich, Italy) + ionomycin (1 μM, Sigma Aldrich, Italy),
Olea (1 μg/ml), Parietaria (1 μg/ml), Graminaceae (1 μg/ml), and Der-
matophagoides (2.5 μg/ml). At the end of the incubation period, su-
pernatants were collected and kept frozen at −30° C until sHLA-G
determination and cells were washed with PBS and used for mem-
brane antigens assessment.
2.3. Flow cytometric analysis
Expression of cell membrane antigens was analyzed by direct im-
munofluorescence incubating PBMC from each individual
(1 × 105 cells in 100 μl of PBS) with the fluorochrome-conjugated
anti-HLA-G monoclonal antibody (mAb) MEM-G9 (Exbio, Czech
Republic), which reacts with the native form of HLA-G1, and with
the fluorochrome-conjugated anti-CD3, -CD4, -CD8, -CD11c, -CD14,
-CD16, -CD19, -CD25, -CD27, -CD45, -CD45RA, -CD56, -CD123,
-HLA DR (Beckman Coulter Europe) mAbs at 4 °C for 30 min in
the dark. For Foxp3 intracellular staining, cells were permeabilized
and fixed using FOXP3 Fix/Perm Buffer Set (Biolegend), accord-
ing to manufacturer’s instructions, then incubated with fluorochrome
conjugated anti-Foxp3 mAb for 30 min at 4 °C in the dark; fluo-
rochrome-conjugated isotype matched Abs were also used as con-
trols. For intracellular staining, after incubation with the primary mAb
cells were fixed and permeabilized with IntraPrep (Beckman Coul-
ter Europe), according to the manufacturer’s instructions, and blocked
with 5% normal goat serum for 20 min on ice to prevent non-specific
antibody binding. Then, anti-interleukin (IL)4, -IL10, -IL17 or -γ-in-
terferon (IFN) (BD Biosciences) mAb was added at 4 °C for 30 min in
the dark. After staining, the analysis was performed by flow cytome-
try using a FC500 flow cytometer equipped with CXP software (Beck-
man Coulter Europe).
2.4. sHLA-G measurements
The determination of sHLA-G molecules was performed by sand-
wich immunoenzymatic assays. A commercially available assay
(Exbio, Czech Republic), which employs the MEM-G9 mAb as cap-
ture antibody, was utilized to determine the amount of sHLA-G1/
HLA-G5 molecules. In order to specifically determine the amount
of sHLA-G1 and HLA-G5 molecules, immunoenzymatic assays were
performed utilizing as capture antibodies the 01G and the 5A6G7
mAbs (Exbio, Czech Republic), which recognize sHLA-G1 and
HLA-G5, respectively. The HRP-conjugated B2M mAb (Exbio,
Czech Republic), which recognizes β2-microglobulin, was employed
as detection antibody in all assays. Plates were read with an ELX800
ELISA reader (BIO-TEK Instrument Inc.) and results were expressed
as U/ml.
2.5. Western blot analysis
PBMC from one patient allergic to Dermatophagoides were incu-
bated for 72 h in culture medium in absence or in presence of the al-
lergens Olea and Dermatophagoides, as previously described. Mono-
cytes, CD4+ T cells and CD8+ T cells were obtained by positive se-
lection using magnetic beads coated with anti-CD14, -CD4 and -CD8
antibodies according to manufacturer’s instructions (Dynabeads). The
221 cell line transfected with HLA-G (221-G) was utilized as posi-
tive control. Cells were lysed in cold buffer (20 mM HEPES, 150 mM
NaCl, 10% [v/v] glycerol, 0.5% [v/v] NP-40, 1 mM EDTA, 2.5 mM
DTT, 10 μg/L aprotinin, leupeptin, pepstatin A, 1 mM PMSF, and
Na3VO4). Protein concentration was determined with the Bredford
protein reagent (BioRad, USA) and 50 μg were resolved by 12%
SDS-polyacrylamide electrophoresis. Then, proteins were transferred
on nitrocellulose membrane (GE Healthcare, Buckinghamshire, Eng-
land) at 4 °C for 45 min. After blocking for 1 h in 5% nonfat dry
milk and washing with Tris-buffer saline-Tween 20 (10 mM Tris-base
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bated with appropriate dilutions of MEM-G1 mAb which recognizes
the HLA-G heavy chain (Exbio) and anti-human actin antibody (Santa
Cruz Biotechnology, Santa Cruz, CA, USA) and finally incubated
with anti-mouse immunoglobulins horseradish peroxidase conjugated
secondary antibody (Santa Cruz Biotechnology). Immunoblots were
developed with Immobilon Western chemiluminescent HRP substrate
(Millipore Billerica, MA, U.S.A.). Band intensities were determined
using IAS 2000 software from Delta Sistemi (Latina, Italy).
2.6. Statistical analysis
Data are reported as mean (±SD). Comparisons between variables
were performed by two-tailed Student’s t test for independent sam-
ples. Statistical significance was assumed for p < 0.05.
3. Results
3.1. Membrane HLA-G expression in in vitro cultured PBMC
In order to analyze the kinetics of HLA-G membrane expression,
preliminary experiments were performed on PBMC from 3 patients
allergic to Parietaria and Dermatophagoides after incubation with as-
pecific stimuli and allergens. A progressive increase in the percentage
of HLA-G-positive cells was observed in CD4+ T lymphocytes (up
to 6%) and in CD14+ monocytes (up to 25%) during 72 h incubation
with the causal allergen (Parietaria and Dermatophagoides) but not
with non causal allergens (Olea and Graminaceae) or aspecific stim-
uli (PHA, PMA + ionomycin and LPS) (Fig. 1). Of interest, a high
percentage (ranging from 34% to 70%) of CD4+HLA-G+T lympho-
cytes showed a strong cytoplasmic positivity for IL4 and IL10, but not
for γIFN and IL17, after incubation with the causal allergen suggest-
ing that these cells should belong to the Th2 lineage (Fig. 2). By con-
trast, CD8+ T lymphocytes, CD19+ B lymphocytes, CD56+ NK cells,
Fig. 1. Representative example of membrane HLA-G expression in CD4+ T lymphocytes (A) and CD14+ monocytes (B) from a patient allergic to Parietaria and Dermatophagoides
after 72 h. incubation with culture medium, phytohemoagglutinin (PHA), phorbol-myristate-acetate + ionomycin (PMA+ IONO), lipopolisaccaride (LPS), Olea, Graminaceae
(Gram), Parietaria (Par) and Dermatophagoides (Derm).
Fig. 2. Cytoplasmic IL4, IL10, IL17 and γIFN expression in CD4+HLA-G+T lymphocytes from a patient allergic to Parietaria and Dermatophagoides after 72 h incubation with the
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CD4+ T regulatory cells (Tregs) including CD4+CD25+FoxP3+,
CD4+CD45RA+CD27+ naïve, CD4+CD45RA−CD27+ central mem-
ory and CD4+CD45RA−CD27− effector memory cells did not show
any detectable HLA-G expression after incubation with aspecific stim-
uli and allergens (data not shown).
Additional experiments indicated that the percentage of HLA-G
positive cells in PBMC from patients allergic to Parietaria and Der-
matophagoides was significantly higher (p < 0.0001) after 72 h incu-
bation with the causal allergen than after incubation with aspecific
stimuli or non causal allergens, the highest HLA-G expression being
observed in monocytes from subjects allergic to Dermatophagoides
(Fig. 3). This latter finding was confirmed by measuring the mean flu-
orescence intensity (MFI) values of HLA-G-positive cells (Table 1).
By contrast, PBMC from patients allergic to Graminaceae showed
only a slight increase in the percentage of HLA-G-positive cells after
incubation with the causal allergen (data not shown).
3.2. Membrane HLA-G expression in circulating PBMC
HLA-G expression was detected in a small number of circulat-
ing CD4+ T cells (about 0.5%) and, among them, in a very low per-
centage (ranging from 0.1 to 0.3%) of CD4+CD45RA+CD27+ or
CD4+CD45RA−CD27+ Tregs. HLA-G expression was not detectable
in circulating CD8+, CD19+, CD56+ cells, in
CD4+CD25+FoxP3+Tregs and in
Fig. 3. Percentage of CD4+HLA-G+T lymphocytes in PBMCs (A) and of CD14+HLA-G+ in monocytes (B) from healthy control subjects and patients allergic to Parietaria, Der-
matophagoides and Parietaria + Dermatophagoides after 72 h incubation with different stimuli. Horizontal bars represent the mean.
Table 1
HLA-G membrane expression in CD4+ T lymphocytes (A) and in CD14+ monocytes (B).
Stimulus Controls (n. 6) Patient’s allegy
Parietaria (n. 6) Dermatophagoides (n. 6) Parietaria and Dermatophagoides (n. 4)
A
Medium 0.35 ± 0.02§ 0.36 ± 0.02 0.36 ± 0.02 0.38 ± 0.03
PHA 0.37 ± 0.05 0.34 ± 0.02 0.35 ± 0.03 0.37 ± 0.04
PMA + ionomycin 0.36 ± 0.01 0.37 ± 0.05 0.36 ± 0.02 0.38 ± 0.01
LPS 0.32 ± 0.01 0.33 ± 0.03 0.35 ± 0.04 0.37 ± 0.05
Parietaria 0.35 ± 0.02 2.17 ± 0.53∗∗ 0.34 ± 0.01 1.99 ± 0.32∗∗
Olea 0.37 ± 0.03 0.36 ± 0.03 0.32 ± 0.01 0.34 ± 0.05
Graminacea 0.34 ± 0.05 0.33 ± 0.02 0.35 ± 0.03 0.36 ± 0.04
Parietaria 0.37 ± 0.03 0.34 ± 0.01 0.36 ± 0.05 0.33 ± 0.02
Dermatophagoides 0.34 ± 0.01 0.36 ± 0.02 2.74 ± 0.94∗∗ 1.72 ± 0.12∗∗
B
Medium 0.33 ± 0.01 0.35 ± 0.02 0.37 ± 0.02 0.52 ± 0.17
PHA 0.37 ± 0.05 0.36 ± 0.04 0.38 ± 0.06 0.39 ± 0.05
PMA + ionomycin 0.35 ± 0.02 0.54 ± 0.31 0.38 ± 0.02 0.66 ± 0.25
LPS 0.42 ± 0.06 0.40 ± 0.04 0.41 ± 0.07 0.43 ± 0.05
Olea 0.37 ± 0.03 0.37 ± 0.05 0.36 ± 0.04 0.38 ± 0.05
Graminacea 0.33 ± 0.01 0.32 ± 0.01 0.37 ± 0.03 0.34 ± 0.02
Parietaria 0.34 ± 0.01 3.91 ± 2.10∗ 0.36 ± 0.01 4.81 ± 2.15∗
Dermatophagoides 0.34 ± 0.02 0.35 ± 0.01 3.00 ± 0.85∗∗ 4.34 ± 2.65∗
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CD3−CD19−CD16−CD56−HLA-DR + CD11c+/CD123+ myeloid or
plasmacytoid dendritic cells (data not shown).
3.3. sHLA-G determination in culture supernatants
In order to analyze the kinetics of sHLA-G release in culture su-
pernatant, preliminary experiments were performed culturing PBMC
from 3 allergic patients with the causal allergen up to 120 h. Re-
sults indicated that a progressive increase of sHLA-G molecules is de-
tectable during the incubation period reaching its maximum after 72 h
(data not shown).
Experiments were then performed incubating for 72 h PBMC from
AR patients in medium alone and in medium supplemented with
the causal allergen or non causal allergen. Results indicated that the
amount of sHLA-G1/HLA-G5 molecules was significantly higher in
the supernatant of PBMC incubated with the causal allergen (p values
ranging from <0.005 to <0.0001) than in the supernatant of PBMC in-
cubated with culture medium or non causal allergen (Table 2). More-
over, these experiments also defined that the supernatant of PBMC
cultured with the causal allergen mainly contained HLA-G5 molecules
(Table 2).
3.4. HLA-G determination by Western blot analysis
Western blot analysis of monocytes, CD4+ T cells and CD8+ T
cells obtained from PBMC of a patient allergic to Dermatophagoides
confirmed that HLA-G is detected in the membrane of monocytes and
CD4+ T cells after incubation with the causal allergen, but not with
non causal allergen (Fig. 4).
4. Discussion
Allergic rhinitis is characterized by a Th-2 polarized inflammation
[40,41]. Allergic patients have also a defect of Tregs that may be re-
stored by specific immunotherapy [51]. HLA-G molecules might play
an important role in the mechanisms of immune tolerance towards al-
lergens as both membrane bound and soluble forms have immuno-
suppressive properties. In fact, it has been demonstrated that anti-
gen presenting cells and monocytes expressing HLA-G molecules are
able to create a tolerogenic milieu enriched in IL-10 which, in turn,
promotes the up-regulation of membrane-bound and soluble HLA-G
and induces Tregs [39]. Moreover, it has been reported that sHLA-G
molecules inhibit the proliferation of T lymphocytes induced by allo-
geneic dendritic cells as well as the activity of cytotoxic T lympho-
cytes and induce apoptosis of T and NK CD8+ cells through CD8 lig-
ation and Fas/sFasL interaction [28–32]. The immunoregulatory prop-
erties of HLA-G have prompted a number of studies aimed at evalu-
ating their cell membrane expression and serum levels in patients af-
fected by a variety of disorders [18–23]. When considering allergic
diseases, elevated levels of sHLA-G molecules have been detected in
plasma and bronchoalveolar lavage fluid of atopic asthmatics [42–45]
and in plasma from AR patients, where their levels correlated with
clinical severity and response to pharmacological therapy [48,49]. Of
interest, specific immunotherapy is able to reduce the sHLA-G anti-
gen levels in serum [50] and in the supernatant from PBMCs stimu-
lated in vitro with allergen [47]. More recently, it has been reported
that patients with seasonal allergic rhinitis had significantly higher
sHLA-G serum levels than patients with perennial allergic rhinitis
[52]. Moreover, it has been showed that there was a moderate rela-
tionship between sHLA-G and allergen-specific IgE levels in patients
with allergic rhinitis and asthma, but there was no difference between
patients with rhinitis and asthmatics [51]. On the basis of this evi
Table 2
sHLA-G level in culture supernatant.
Patient’s allergy Stimulus sHLA-G1/G5 sHLA-G1 sHLA-G5
Parietaria Medium 2.03 ± 0.55§ 1.77 ± 0.53 0.24 ± 0.01
Parietaria 38.98 ± 18.64∗∗ 2.45 ± 0.66 31.41 ± 18.00∗∗
Dermatophagoides 2.42 ± 0.80 1.69 ± 0.64 0.53 ± 0.47
Dermatophagoides Medium 2.87 ± 0.91 1.52 ± 0.22 0.25 ± 0.01
Parietaria 3.84 ± 1.96 1.88 ± 0.29 2.17 ± 2.61
Dermatophagoides 30.62 ± 10.02∗∗ 3.07 ± 0.58 23.21 ± 4.49∗∗
Parietaria and Dermatophagoides Medium 1.81 ± 0.47 1.40 ± 0.23 0.23 ± 0.02
Parietaria 52.96 ± 24.32∗ 3.00 ± 0.88 51.15 ± 23.25∗
Dermatophagoides 41.38 ± 12.37∗∗ 2.54 ± 1.47 40.88 ± 13.24∗∗
§ Values are expressed as mean (±SD) U/ml;*p < 0.005 and **p < 0.0001 as compared to medium and/or non causal allergen.
Fig. 4. Western blot analysis of monocytes (lane 1), CD4+ T cells (lane 2) and CD8+ T cells (lane 3) from a Dermatophagoides allergic patient after 72 h of incubation in absence
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dence, it has been suggested that sHLA-G might be considered a bio-
marker of allergic reaction.
The present study was aimed at evaluating the in vitro expres-
sion and release of HLA-G molecules by PBMC after incubation with
both allergenic and non-allergenic stimuli in AR patients exposed or
not to the causal allergen. HLA-G membrane expression was specif-
ically induced by incubation with the causal allergen, but not by in-
cubation with non-causal allergens or non-specific stimuli, underlin-
ing the specificity of the immune response to allergens. Of interest,
only CD4+ T cells, in particular Th-2 cells, and monocytes expressed
HLA-G after allergenic challenge whereas CD8+ T lymphocytes, B
lymphocytes, NK cells and Tregs did not show any detectable HLA-G
expression after incubation with aspecific stimuli and allergens. No-
tably, monocytes expressed HLA-G at higher levels than CD4+ T
lymphocytes suggesting that these cells could be the most relevant
source of HLA-G production. The exposure to the causal allergen
seems to be the main factor inducing HLA-G expression. In fact, pa-
tients allergic to mites, evaluated during winter when the exposure to
mite was still present, showed the more intense membrane HLA-G ex-
pression, whereas grass pollen allergic patients, who were evaluated
far from the pollen season, showed a very low increase of HLA-G ex-
pression.
The measurement of sHLA-G in culture supernatants confirmed
the cell membrane results, the highest amount of sHLA-G molecules
being found when the causal allergen was used as stimulus. Of note,
soluble molecules detected in culture supernatants mainly belong to
the HLA-G5 isoform strongly suggesting that they are actively se-
creted by immune cells after incubation with allergen.
On the basis of this in vitro study we could hypothesize that
HLA-G molecules might play a role also in allergic reaction in vivo.
This hypothesis is consistent with a series of in vivo studies showing
that sHLA-G serum level is increased in allergic patients and corre-
lates with clinical severity, drug use, allergen-specific IgE levels, type
of allergy, and response to immunotherapy [48–52].
At present, the role of membrane bound and soluble HLA-G mole-
cules in immunoregulation appears complex and not univocal. In fact,
although HLA-G molecules mainly exert immunosuppressive effects
[28–33], they may also play an immunoregulatory role [36–39] by tun-
ing immune responses towards either a Th-2 or a Th-1 cytokine pro-
file [34,35]. Accordingly, it has been recently proposed that HLA-G
should be no longer qualified as a “shield” to protect tissues and cells
from immune destruction but, rather, as an “immune checkpoint” mol-
ecule [53]. The results of our in vitro experiments may suggest that the
expression and secretion of HLA-G molecules may contribute to the
Th-2 shift which characterizes the allergic reaction.
In conclusion, the present study provides the first in vitro evidence
that: i) HLA-G is specifically expressed and released by PBMC af-
ter stimulation with the causal allergen; ii) the main source of HLA-G
molecules are monocytes and, to a lesser extent, CD4+ Th-2 cells; iii)
the natural allergen exposure significantly affects HLA-G expression
and release. Further studies are needed to better clarify the functional
role of HLA-G in allergic diseases.
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